MedTrace Logo

Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain

NCT04466410 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-01-23

No results posted yet for this study

Summary

Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Neuropathic Pain. Intrathecally administered, single injection.

Conditions

  • Neuropathic Pain

Interventions

BIOLOGICAL

XT-150

Single bolus intrathecal injection

BIOLOGICAL

Placebo

Placebo is a sterile phosphate-buffered saline

Sponsors & Collaborators

  • Xalud Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Howard Rutman, MD,MBA · Xalud Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-14
Primary Completion
2022-09-27
Completion
2022-09-27

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04466410 on ClinicalTrials.gov